건강 보험 청구 자료를 이용한 COPD 환자에서 치료제 처방 변화 분석: 흡입제를 중심으로
Analysis of Treatment Pattern in COPD Patients Using Health Insurance Claims Data: Focusing on Inhaled Medications
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background: Chronic obstructive pulmonary disease (COPD) is not completely reversible and requires long-term management withappropriate treatment. This study aimed to analyze trends in treatment regimens and medication costs for COPD patients using anational claims database. Methods: We conducted this analysis using National Patient Sample data from the Health InsuranceReview and Assessment Service covering the period from 2015 to 2018. We have constructed a dataset comprising COPD diseaseclassification codes J43.x and J44.x (based on KCD-7 code, J43.0 was excluded) and compiled a list of drugs fitting currentguidelines. To identify trends, we calculated frequency, ratio, and compound annual growth rate (CAGR) using the numbers ofprescriptions and patients. Results: The number of COPD patients was 7,260 in 2018, slightly decreased from 2015. Most of theseCOPD patients were aged 60 or older and included a high proportion of males (72.2%; 2018). The number of patients prescribedinhaled medications increased gradually from 2015 to 2018 (9,227 (47.1%); 2015, 9,285 (51.5%); 2018), while the number ofpatients prescribed systemic beta-agonists and Xanthines has decreased since 2015 (CAGR −14.7; systemic beta-agonist, −5.8;Xanthines). The per capita cost of medication has increased by 0.4% (KRW 206,667; 2018, KRW 204,278; 2015) annually duringthe study period. Conclusion: This study showed that treatment with inhaled medications had continuously increased in accord withchanging guidelines, but oral medications were still widely used. It is necessary to emphasize the importance of inhaled medicationsin treating COPD to reduce additional economic burden through appropriate medication use.
Abstract
Background: Chronic obstructive pulmonary disease (COPD) is not completely reversible and requires long-term management withappropriate treatment. This study aimed to analyze trends in treatment regimens and medication costs for COPD patients using anational claims database. Methods: We conducted this analysis using National Patient Sample data from the Health InsuranceReview and Assessment Service covering the period from 2015 to 2018. We have constructed a dataset comprising COPD diseaseclassification codes J43.x and J44.x (based on KCD-7 code, J43.0 was excluded) and compiled a list of drugs fitting currentguidelines. To identify trends, we calculated frequency, ratio, and compound annual growth rate (CAGR) using the numbers ofprescriptions and patients. Results: The number of COPD patients was 7,260 in 2018, slightly decreased from 2015. Most of theseCOPD patients were aged 60 or older and included a high proportion of males (72.2%; 2018). The number of patients prescribedinhaled medications increased gradually from 2015 to 2018 (9,227 (47.1%); 2015, 9,285 (51.5%); 2018), while the number ofpatients prescribed systemic beta-agonists and Xanthines has decreased since 2015 (CAGR −14.7; systemic beta-agonist, −5.8;Xanthines). The per capita cost of medication has increased by 0.4% (KRW 206,667; 2018, KRW 204,278; 2015) annually duringthe study period. Conclusion: This study showed that treatment with inhaled medications had continuously increased in accord withchanging guidelines, but oral medications were still widely used. It is necessary to emphasize the importance of inhaled medicationsin treating COPD to reduce additional economic burden through appropriate medication use.
참고문헌 (23)
- 박용범, "Revised (2018) COPD Clinical Practice Guideline of the Korean Academy of Tuberculosis and Respiratory Disease: A Summary", Tuberculosis and Respiratory Diseases, 81(4), pp.261~273 (2018), 대한결핵및호흡기학회
- Denguezli M, "Prevalence and characteristics of undiagnosed COPD in adults 40 years and older –reports from the Tunisian population-based burden of obstructive lung disease study", COPD, 17(5), pp.515~522 (2020)
- "2020 Current Status and Issues of Chronic Diseases"[URL]
- 안태준, "만성폐쇄성폐질환의 유병률 및 사회 경제적 부담", 대한의사협회지, 61(9), pp.533~538 (2018), 대한의사협회[DOI]
- 황용일, "Recent Trends in the Prevalence of Chronic Obstructive Pulmonary Disease in Korea", Tuberculosis and Respiratory Diseases, 80(3), pp.226~229 (2017), 대한결핵및호흡기학회
- Lee JM, "Trend of cost and utilization of COPD medication in Korea", Int J Chron Obstruct Pulmon Dis, 12, pp.27~33 (2016)
- Kim JE, "Analysis of drug costs and trends in use of COPD", HIRA Policy Brief, 11(1), pp.42~59 (2017)
- 김강혁, "The Effect of Asthma Clinical Guideline for Adults on Inhaled Corticosteroids PrescriptionTrend: A Quasi-Experimental Study", Journal of Korean Medical Science, 30(8), pp.1048~1054 (2015), 대한의학회
- 조상헌, "The Current Status of Asthma in Korea", Journal of Korean Medical Science, 21(2), pp.181~187 (2006), 대한의학회
- Scanlon PD, "Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study", Am J Respir Crit Care Med, 161(2 Pt 1), pp.381~390 (2000)
- Nannini LJ, "Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease", Cochrane Database Syst Rev, 2012(9), pp.CD006829~ (2012)
- Calverley PMA, "TORCH investigators, Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease", N Engl J Med, 356(8), pp.775~789 (2007)
- Wedzicha JA, "Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD", N Engl J Med, 374(23), pp.2222~2234 (2016)
- 이기동, "만성 폐쇄성 폐질환의 의료이용 현황 및 관련 요인: 전국조사를 통한 1990년에서 2008년까지 변화추이", Tuberculosis and Respiratory Diseases, 70(4), pp.307~314 (2011), 대한결핵및호흡기학회
- National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health, "The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General" (2014), Centers for Disease Control and Prevention(US)
- "Health Insurance Review & Assessment Service-Results of adequacy evaluation of chronic obstructive pulmonary disease in 2019"[URL]
- Suissa S, "Inhaled corticosteroids in COPD and the risk of serious pneumonia", Thorax, 68(11), pp.1029~1036 (2013)
- "Global Initiative for Chronic Obstructive Lung Disease-Global Strategy for the diagnosis management, and prevention of chronic obstructive pulmonary disease :2019 Report"[URL]
- Zhang S, "Impact of single combination inhaler versus multiple inhalers to deliver the same medications for patients with asthma or COPD : A systematic literature review", Int J Chron Obstruct Pulmon Dis, 15, pp.417~438 (2020)
- Cho KS, "Current Status of Chronic Obstructive Pulmonary Disease(COPD)in the Republic of Korea", Public Health Weekly Report, 14(16), pp.943~951 (2021)
- "Global Strategy for Prevention, Diagnosis and Management of COPD: 2022 Report"[URL]
- Price D, "Earlier diagnosis and earlier treatment of COPD in primary care", Prim Care Respir J, 20(1), pp.15~22 (2011)
- Csikesz NG, "New developments in the assessment of COPD : early diagnosis is key", Int J Chron Obstruct Pulmon Dis, 9, pp.277~286 (2014)